However, CMS clarified in a memo dated March 20, 2024, that anti-obesity medications that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use. As of August 19, 2024, the only GLP-1 RA this applies to is Wegovy, which, in addition to its obesity indication, is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
(PubMed) Fu JY, Che HL, Tan DM, Teng KT
Vitamin B12 promotes the metabolism of carbs, fats, and proteins, which in turn helps relieve fatigue and provide the body with energy to function and carry out daily processes
We simply do not know how weight-loss medication interacts with those processes or whether it could affect normal physiological recovery, Dr
Lindsay36840 19 June 2019 10:16 15 Lipo batteries are unforgiving